Cytek Biosciences to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Cytek Biosciences to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Cytek Biosciences (Nasdaq: CTKB) is a leading cell analysis solutions company advancing the next generation of cell analysis tools by delivering high-resolution, high-content and high-sensitivity cell analysis utilizing its patented Full Spectrum Profiling (FSP) technology. Cytek's novel approach harnesses the power of information within the entire spectrum of a fluorescent signal to achieve a higher level of multiplexing with precision and sensitivity. Cytek's platform includes its core FSP instruments, the Cytek Aurora and Northern Lights systems and its Cytek Aurora CS cell sorter; the Cytek Orion reagent cocktail preparation system; the Enhanced Small Particle (ESP) detection technology; the flow cytometer and imaging products under the Amnis and Guava brands; and reagents, software and service to provide a comprehensive and integrated suite of solutions for its customers. Cytek is headquartered in Fremont, California with offices and distribution channels across the globe. More information about the company and its products is available at .FREMONT, Calif., Jan. 02, 2025 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (Nasdaq: CTKB), a leading cell analysis solutions company, today announced the company will be participating in the upcoming 43rd Annual J.P. Morgan Healthcare Conference in San Francisco, CA.
加利福尼亞州弗裏蒙特，2025年1月2日（GLOBE NEWSWIRE）——領先的細胞分析解決方案公司Cytek Biosciences, Inc.（納斯達克股票代碼：CTKB）今天宣佈，該公司將參加即將在加利福尼亞州舊金山舉行的第43屆摩根大通醫療保健年度會議。
Cytek management is scheduled to present on Thursday, January 16th at 8:15 a.m. Pacific Time / 11:15 a.m. Eastern Time. Interested parties may access a live and archived webcast of the presentation on the "Investors" section of the company website at: investors.cytekbio.com.
Cytek管理層定於太平洋時間1月16日星期四上午8點15分/美國東部時間上午11點15分發表講話。有興趣的人士可以在公司網站的 「投資者」 欄目上觀看該演講的網絡直播和存檔直播，網址爲：investors.cytekbio.com。
About Cytek Biosciences, Inc.
關於 Cytek Biosciences, Inc
Cytek Biosciences (Nasdaq: CTKB) is a leading cell analysis solutions company advancing the next generation of cell analysis tools by delivering high-resolution, high-content and high-sensitivity cell analysis utilizing its patented Full Spectrum Profiling (FSP) technology. Cytek's novel approach harnesses the power of information within the entire spectrum of a fluorescent signal to achieve a higher level of multiplexing with precision and sensitivity. Cytek's platform includes its core FSP instruments, the Cytek Aurora and Northern Lights systems and its Cytek Aurora CS cell sorter; the Cytek Orion reagent cocktail preparation system; the Enhanced Small Particle (ESP) detection technology; the flow cytometer and imaging products under the Amnis and Guava brands; and reagents, software and service to provide a comprehensive and integrated suite of solutions for its customers. Cytek is headquartered in Fremont, California with offices and distribution channels across the globe. More information about the company and its products is available at .
Cytek Biosciences（納斯達克股票代碼：CTKB）是一家領先的細胞分析解決方案公司，通過利用其專利的全光譜分析（FSP）技術提供高分辨率、高內容和高靈敏度的細胞分析，推動下一代細胞分析工具的發展。Cytek的新方法利用熒光信號整個光譜中的信息力量，以精度和靈敏度實現更高水平的多路傳輸。Cytek的平台包括其核心FSP儀器、Cytek Aurora和北極光系統及其Cytek Aurora CS細胞分選器；Cytek Orion試劑雞尾酒製備系統；增強型小顆粒（ESP）檢測技術；Amnis和Guava品牌的流式細胞儀和成像產品；以及爲其客戶提供全面和綜合解決方案套件的試劑、軟體和服務。Cytek 總部位於加利福尼亞州弗裏蒙特，在全球設有辦事處和分銷渠道。有關該公司及其產品的更多信息，請訪問。
Cytek's products are for research use only and not for use in diagnostic procedures (other than Cytek's Northern Lights-CLC system and certain reagents, which are available for clinical use in China and the European Union).
Cytek的產品僅用於研究用途，不用於診斷程序（Cytek的Northern Lights-CLC系統和某些試劑除外，這些試劑可在中國和歐盟臨牀使用）。
Cytek, Full Spectrum Profiling, FSP, Cytek Aurora, Northern Lights, Cytek Orion, Enhanced Small Particle, ESP, Amnis and Guava are trademarks of Cytek Biosciences, Inc.
Cytek、全光譜分析、FSP、Cytek Aurora、北極光、Cytek Orion、增強型小粒子、ESP、Amnis 和 Guava 是 Cytek Biosciences, Inc. 的商標。
In addition to filings with the Securities and Exchange Commission (SEC), press releases, public conference calls and webcasts, Cytek uses its website (), LinkedIn page and X (formerly Twitter) account as channels of distribution of information about its company, products, planned financial and other announcements, attendance at upcoming investor and industry conferences and other matters. Such information may be deemed material information and Cytek may use these channels to comply with its disclosure obligations under Regulation FD. Therefore, investors should monitor Cytek's website, LinkedIn page, and X account in addition to following its SEC filings, news releases, public conference calls and webcasts.
除了向美國證券交易委員會（SEC）提交文件、新聞稿、公開電話會議和網絡直播外，Cytek還使用其網站（）、LinkedIn頁面和X（前身爲Twitter）賬戶作爲發佈有關其公司、產品、計劃財務和其他公告、出席即將舉行的投資者和行業會議以及其他事項的信息的渠道。此類信息可能被視爲重要信息，Cytek可以使用這些渠道來履行其在FD法規下的披露義務。因此，投資者除了關注其向美國證券交易委員會提交的文件、新聞稿、公開電話會議和網絡直播外，還應監控Cytek的網站、LinkedIn頁面和X賬戶。
Media Contact:
Stephanie Olsen
Lages & Associates
(949) 453-8080
stephanie@lages.com
媒體聯繫人：
斯蒂芬妮·奧爾森
拉格斯與同事
(949) 453-8080
stephanie@lages.com
Investor Contact:
Paul Goodson
Head of Investor Relations
Cytek Biosciences
pgoodson@cytekbio.com
投資者聯繫方式：
保羅·古德森
投資者關係主管
Cytek 生物科學
pgoodson@cytekbio.com
